Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance

By Pebody R.G.   Gay N.J.   Hesketh L.M.   Vyse A.   Morgan-Capner P.   Brown D.W.   Litton P.   Miller E.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1134-1140

Elsevier

Access to resources Recommend Favorite

Reactogenicity and immunogenicity of a new combined Measles-Mumps-Rubella vaccine: results of a multicentre trial

By Crovari P.   Gabutti G.   Giammanco G.   Dentico P.   Moiraghi A.R.   Ponzio F.   Soncini R.  

Vaccine, Vol. 18, Iss. 25, 2000-06 ,pp. : 2796-2803

Elsevier

Access to resources Recommend Favorite

Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months

By Forleo-Neto E.   Carvalho E.S.   Fuentes I.C.P.   Precivale M.S.   Forleo L.H.A.   Farhat C.K.  

Vaccine, Vol. 15, Iss. 17, 1997-12 ,pp. : 1898-1901

Elsevier

Access to resources Recommend Favorite

Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age *

By Klinge  

Vaccine, Vol. 18, Iss. 27, 2000-07 ,pp. : 3134-3140

Elsevier

Access to resources Recommend Favorite

Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination

By Boulianne N.   De Serres G.   Duval B.   Ratnam S.   Ward B.J.   Joly J.R.  

Vaccine, Vol. 13, Iss. 16, 1995-11 ,pp. : 1611-1616

Elsevier

Access to resources Recommend Favorite